Low oral poliovirus vaccine immunogenicity in developing countries
Orenstein, W.A.; Garon, J.R.
LANCET. Infectious Diseases 16(8): 868-869
2016
ISSN/ISBN: 1474-4457 PMID: 27156190 DOI: 10.1016/s1473-3099(16)30050-0Document Number: 419416
Document emailed within 0-6 h
Related Documents
Lin, T.-Y.; Wang, Y.-H.; Chang, L.-Y.; Chiu, C.-H.; Huang, Y.-C.; Tang, H.; Bock, H.L. 2003: Safety and immunogenicity of a diphtheria, tetanus, and acellular pertussis-inactivated poliovirus vaccine/Haemophilus influenzae type B combination vaccine administered to Taiwanese infants at 2, 4, and 6 months of age Chang Gung Medical Journal 26(5): 315-322Friedrich, F. 2000: Molecular evolution of oral poliovirus vaccine strains during multiplication in humans and possible implications for global eradication of poliovirus Acta Virologica 44(2): 109-117
Chowdhary, R.; Dhole, T.N. 2008: Interrupting wild poliovirus transmission using oral poliovirus vaccine: environmental surveillance in high-risks area of India Journal of Medical Virology 80(8): 1477-1488
Más Lago, P.; Díaz, J.; Díaz Gonzalez, M.; Goyenechea Hernández, A.; Barrio Olivera, J.; Fonseca Quintana, M.; Morier Díaz, L.; Sarmiento Pérez, L.; Palomera Puente, R. 2005: Isolates of poliovirus vaccine and immune response to different doses of oral polio vaccine Revista Cubana de Medicina Tropical 57(2): 111-119
Troy, S.B.; Musingwini, G.; Halpern, M.S.; Huang, C.; Stranix-Chibanda, L.; Kouiavskaia, D.; Shetty, A.K.; Chumakov, K.; Nathoo, K.; Maldonado, Y.A. 2013: Vaccine poliovirus shedding and immune response to oral polio vaccine in HIV-infected and -uninfected Zimbabwean infants Journal of Infectious Diseases 208(4): 672-678
Metselaar, D. 1976: Selection of virulent poliovirus strains in developing countries? A hypothesis Nederlands Tijdschrift Voor Geneeskunde 120(46): 1990-1995
Dreazen, J.R. 1999: Cost of inactivated vs. oral poliovirus vaccine American Family Physician 60(7): 1929; 1932
Lasch, E.E.; Abed, Y.; Marcus, O.; Gerichter, C.B.; Melnick, J.L. 1986: Combined live and inactivated poliovirus vaccine to control poliomyelitis in a developing country--five years after Developments in Biological Standardization 65: 137-143
Pollak, O.; Power, D.J.; Bundred, P.; Joosting, A.C. 1980: Serum antibody levels after immunization with trivalent oral poliovirus vaccine South African Medical Journal 57(6): 191-193
Levenbook, I.; Nomura, T. 1997: Development of a neurovirulent testing system for oral poliovirus vaccine with transgenic mice Laboratory Animal Science 47(2): 118-120
Dowdle, W.R.; Wolff, C.; Sanders, R.; Lambert, S.; Best, M. 2004: Will containment of wild poliovirus in laboratories and inactivated poliovirus vaccine production sites be effective for global certification? Bulletin of the World Health Organization 82(1): 59-62
Crainic, R.; Wu, R.; Otelea, D.; Georgescu, M.M.; Delpeyroux, F.; Guillot, S.; Balanant, J.; Tardy-Panit, M. 1996: The replacement of water with deuterium oxide significantly improves the thermal stability of the oral poliovirus vaccine Developments in Biological Standardization 87: 161-166
John, T.Jacob.; Jain, H.; Ravishankar, K.; Amaresh, A.; Verma, H.; Deshpande, J.; Pallansch, M.A.; Singh, A.Pal.; Sreevatsava, M.; Burton, A.; Malankar, P.; Chatterjee, A.; Sutter, R.W. 2011: Monovalent type 1 oral poliovirus vaccine among infants in India: report of two randomized double-blind controlled clinical trials Vaccine 29(34): 5793-5801
Rumiantsev, A.A.; Grachev, V.P.; Kozlov, V.G.; Karganova, G.G. 2001: Use of molecular biological method (MAPREC-test) for evaluating residual neurovirulence and genetic stability of oral poliovirus vaccine type 3 Voprosy Virusologii 46(6): 11-15
Esparza, Jé.; Osmanov, S.; Pattou-Markovic, C.; Touré, C.; Chang, M.Louise.; Nixon, S. 2002: Past, present and future of HIV vaccine trials in developing countries Vaccine 20(15): 1897-1898
Termrungruanglert, W.; Havanond, P.; Khemapech, N.; Lertmaharit, S.; Pongpanich, S.; Khorprasert, C.; Taneepanichskul, S. 2012: Cost and effectiveness evaluation of prophylactic HPV vaccine in developing countries Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research 15(1 Suppl): S29-S34
Stover, J.; Bollinger, L.; Hecht, R.; Williams, C.; Roca, E. 2007: The impact of an AIDS vaccine in developing countries: a new model and initial results Health Affairs 26(4): 1147-1158
Ahmed, T.; Svennerholm, A-Mari.; Al Tarique, A.; Sultana, G.N.N.; Qadri, F. 2009: Enhanced immunogenicity of an oral inactivated cholera vaccine in infants in Bangladesh obtained by zinc supplementation and by temporary withholding breast-feeding Vaccine 27(9): 1433-1439
Valencia-Mendoza, A.; Bertozzi, S.M.; Gutierrez, J.-P.; Itzler, R. 2008: Cost-effectiveness of introducing a rotavirus vaccine in developing countries: the case of Mexico Bmc Infectious Diseases 8: 103
1995: Tetanus vaccine may be laced with anti-fertility drug. International / developing countries Vaccine weekly 1995: 9-10